Reglagene isn't just another biotech startup—it's a surgical strike on the hardest problem in pharmaceuticals: getting drugs past the blood-brain barrier. With $13.6M in funding and a team of 17, they're operating in stealth mode while their website quietly attracts 472 monthly visits from a hyper-targeted audience.

"They're not building a website—they're building a pipeline. The traffic numbers prove it's not about marketing; it's about science."

The tech stack tells its own story. They're built on Squarespace with Tailwind CSS and Bootstrap—practical choices for a lean biotech that needs to look credible without burning cash on custom development. Google Analytics tracks every visitor, but with only 472 monthly visits, they're clearly not optimizing for scale. The real question is whether this minimalist digital presence is strategic stealth or a missed opportunity for talent acquisition.

• Brain-penetrant medicines: Their core IP addresses the industry's biggest bottleneck
• Tubulin targeting: A specific mechanism that's gaining traction in CNS disorders
• Stealth mode operations: Minimal public footprint suggests they're in preclinical/early clinical stages
• Founder-driven traffic: 'Matt Marx' searches dominate their organic presence